Business NewsPR NewsWire • Dutch Amarna Therapeutics enters research collaboration with Spanish FPS, examining the efficacy of its SV40-based SVec™ gene delivery vector platform technology in diabetes mellitus type 1 and multiple sclerosis

Dutch Amarna Therapeutics enters research collaboration with Spanish FPS, examining the efficacy of its SV40-based SVec™ gene delivery vector platform technology in diabetes mellitus type 1 and multiple sclerosis

Dutch Amarna Therapeutics enters research collaboration with Spanish FPS, examining the efficacy of its SV40-based SVec™ gene delivery vector platform technology in diabetes mellitus type 1 and multiple sclerosis

LEIDEN, The Netherlands and SEVILLE, Spain, Sept. 25, 2020 /PRNewswire/ -- Amarna Therapeutics, a Dutch privately held biotechnology company developing the next-generation SV40-based gene delivery vector platform transforming gene-replacement and immunotherapy across many disease areas....

View More : https://www.prnewswire.com:443/news-releases/dutch-amarna-therapeutics-enters-research-collaboration-with-spanish-fps-ex...
Releted News by prnewswire
Launch of all-electric EcoMax™ urban air mobility set for second quarter of 2021
Radius Health & Menarini Group Provide Elacestrant Update
Dutch Amarna Therapeutics enters research collaboration with Spanish FPS, examining the efficacy of its SV40-based SVec™ gene delivery vector platform technology in diabetes mellitus type 1 and multiple sclerosis
Immunovia Announces Positive Results from the IMMray™ PanCan-d Verification Study
Enesi Pharma's ImplaVax®-Enabled, Solid-Dose Modified Live Virus Vaccine Produces Neutralising Antibody and T-Cell Responses Equivalent to Liquid Vaccine Delivered via Needle and Syringe